

EMOTRA AB: Results of the rights issue

The subscription period for Emotra AB's ("Emotra") rights issue expired on June 21, 2017. The upper limit for this rights issue was approximately 17.5 MSEK. Emotra received applications totalling approximately 13.8 MSEK, or 79% of the maximum issue amount. 4,184,399 new shares will be issued in this rights issue, providing Emotra with about 13.8 MSEK in new funds before issue costs, which will amount to approximately 1.2 MSEK. We plan on sending out account statements today, June 27, 2017.

Comments from Claes Holmberg, Emotra's CEO

"I would like to thank everyone who has chosen to invest in Emotra. The funds that this issue brings to the Company will allow us to leverage the potential we see for EDOR® and initiate our market launch of the method. We have seen a keen interest among psychiatric clinics, both in participating in the trainings we host as part of our marketing activities and in getting started with EDOR®. Our goal is to achieve a broad market acceptance of our method among leading psychiatric clinics in the west."

Subscription and allotment

Including subscription commitments, Emotra received applications totalling approximately 13,808,516.70 SEK, or 79% of the maximum issue amount. 4,184,399 new shares will be issued, providing Emotra with about 13.8 MSEK in new funds before issue costs, which are estimated to amount to about 1.2 MSEK. 3,704,723 shares (corresponding to 70%) were allocated through right of priority. The new shares will be allocated in accordance with the allocation principles described in the Company's memorandum. Those who have applied for shares without right of priority will be receiving account statements. We expect to send these account statements out today, June 27, 2017. Applicants who are not allocated any shares will not receive an account statement.

Number of Shares and share capital

Once this rights issue has been registered with Bolagsverket (The Swedish Companies Registration Office), Emotra's share capital will amount to 2,534,917.92 SEK, divided among 13,702,259 shares.

Trading in PSS

Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget until the rights issue has been registered at Bolagsverket. We expect this registration to be completed in the middle of July 2017.

Financial Advisor

Emotra's Financial Advisor in connection with this new rights issue is Sedermera Fondkommission.

For further information about the rights issue, please contact:

Sedermera Fondkommission
Telephone: +46 40 615 14 10
E-mail: info@sedermera.se

For further information about Emotra, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on June 27, 2017 under the above contact's supervision.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

